[Rosuvastatin in patients with chronic heart failure].
Hoppe
U C
UC
Klinik III für Innere Medizin, Universität zu Köln, Kerpener Strasse 62, Köln, Germany. Uta.Hoppe@uni-koeln.de
Nitschmann
S
S
D000368:Aged; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D007558:Italy; D008297:Male; D016016:Proportional Hazards Models; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium